Clinical trial
Serotonin/Dopamine Antagonism of Cocaine Effect: 2 - 2
NCT00000310 · National Institute on Drug Abuse (NIDA), NIH · Terminated
Key facts
| NCT number | NCT00000310 |
|---|---|
| Title | Serotonin/Dopamine Antagonism of Cocaine Effect: 2 - 2 |
| Official title | Serotonin/Dopamine Antagonism of Cocaine Effect |
| Lead sponsor | National Institute on Drug Abuse (NIDA), NIH |
| Collaborators | VA Boston Healthcare System U.S. Fed |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Cocaine-Related Disorders |
| Intervention type | Drug |
| Interventions | Risperidone |
| Enrollment | 0 |
| Start date | Jan 1, 1996 |
| Primary completion | Mar 1, 1996 |
| Completion | Mar 1, 1996 |
| First posted | Sep 21, 1999 |
| Last update posted | Jan 16, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: